Loss of the Tumor Suppressor HACE1 Contributes to Cancer Progression
| Autor: | Jun-Chen Li, Yang Chen, Xiang-Lian Zhang, Shi-Ming Yang, Chang-Jiang Hu, Xinzhe Li, Xing Chang, Hao Zhang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Tumor suppressor gene Ubiquitin-Protein Ligases Clinical Biochemistry Down-Regulation Inflammation law.invention Metastasis Epigenesis Genetic 03 medical and health sciences 0302 clinical medicine Ubiquitin law Neoplasms Drug Discovery Medicine Humans Tumor growth Pharmacology biology business.industry Cancer DNA Methylation medicine.disease Gene Expression Regulation Neoplastic 030104 developmental biology 030220 oncology & carcinogenesis Gene Knockdown Techniques DNA methylation Cancer research biology.protein Disease Progression Molecular Medicine Suppressor medicine.symptom business |
| Zdroj: | Current drug targets. 20(10) |
| ISSN: | 1873-5592 |
| Popis: | HACE1 belongs to the family of HECT domain-containing E3 ligases, which plays an important role in the occurrence, invasion and metastatic process in many human malignancies. HACE1 is a tumor suppressor gene that is reduced in most cancer tissues compared to adjacent normal tissue. The loss or knocking out of HACE1 leads to enhanced tumor growth, invasion, and metastasis; in contrast, the overexpression of HACE1 can inhibit the development of tumors. Hypermethylation reduces the expression of HACE1, thereby promoting tumor development. HACE1 can inhibit the development of inflammation or tumors via the ubiquitination pathway. Therefore, HACE1 may be a potential therapeutic target, providing new strategies for disease prevention and treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|